Target
CSF-1R
17 abstracts
Abstract
First-in-human study of simmitinib, a novel tyrosine kinase inhibitor targeting FGFR1-3, KDR and CSF-1R.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China, Harbin Medical University Cancer Hospital, Harbin, China, The Second Affiliated Hospital of Anhui Medical University, Hefei, China, Chongqing University Cancer Hospital, Chongqing, China, Phase I Clinical Trial Center, Chongqing University Cancer Hospital, Chongqing, China, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, Henan Cancer Hospital, Zhengzhou, China, Shandong Provincial Institute of Cancer Prevention and Treatment, Jinan, China, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China, Fujian Provincial Cancer Hospital, Fuzhou, China, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Yunnan Cancer Hospital, Yunnan, China, First Affiliated Hospital Of Gannan Medical University, Ganzhou, China, CSPC Pharmaceutical Group Limited, Shijiazhuang, China, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
Phase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma that has failed standard chemotherapy: Updated analysis.Org: Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, China, Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China,
Abstract
Efficacy and safety of surufatinib, toripalimab, nab-paclitaxel in combination with radiotherapy or surgery in the first-line treatment of esophageal squamous cell cancer: A single-centered prospective clinical trial.Org: Chinese PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
Efficacy and safety of surufatinib combined with EP regimen and serplulimab in first-line treatment of NEC.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital,
Abstract
Surufatinib combined with TAS-102 in third- or later-line therapy of patients with metastatic pancreatic cancer (mPDAC): An open-label, single-arm, phase II study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,
Abstract
A phase I/II study of C019199 in combination with sintilimab in advanced malignancy.Org: The First Affiliated Hospital of Xiamen University, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,
Abstract
Updated efficacy and safety results from the phase Ib/II study of surufatinib combined with camrelizumab and chemotherapy in patients with advanced colorectal cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Jiangsu Cancer Hospital, Nanjing, China,
Abstract
Surufatinib plus PD-1/L1 inhibitors as maintenance therapy following first line (1L) platinum-based chemotherapy combined with PD-1/L1 inhibitors in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC).Org: Department of Respiratory Medicine,Taizhou Hosipital of Zhejiang Province, The Fifth Medical Center of the Chinese People's Liberation Army General Hospital, The Southwest Hospital of AMU,
Abstract
Surufatinib monotherapy or combined with vinorelbine as a late-line therapy in patients with refractory advanced non–small cell lung cancer (NSCLC).Org: Affiliated Cancer Hospital & Institute of Guangzhou Medical University,
Abstract
A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer.Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, West China Hospital, Sichuan University, Chengdu, China, The First Affiliated Hospital of Xiamen University, Xiamen, China, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China, Beijing Cancer Hospital, Beijing, China,
Abstract
A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.Org: Fudan University Shanghai Cancer Center, The First Affiliated Hospital of Zhengzhou University, Department of Oncology, Jilin Cancer Hospital, Changchun, China, Jilin Cancer Hospital, HUTCHMED Limited,
Abstract
First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.Org: Sarah Cannon Research Institute at HealthONE, Denver, CO, Jiangsu Province Hospital, Nanjing, China, Winship Cancer Institute, Atlanta, GA, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Henan Cancer Hospital, Zhengzhou, China,
Abstract
Efficacy and safety profile of pimicotinib (ABSK021) in tenosynovial giant cell tumor (TGCT): Phase 1b update.Org: Abbisko Therapeutics Co., Ltd., Shanghai, China,
Abstract
A phase II study of durvalumab (MEDI4736) in combination with a CSF-1R inhibitor (SNDX-6352) following chemotherapy or radio-embolization for patients with intrahepatic cholangiocarcinoma.Org: Johns Hopkins University Bloomberg School of Public Health, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine,
Abstract
A phase II study of surufatinib in patients with osteosarcoma and soft tissue sarcoma who have experienced treatment failure with standard chemotherapy.Org: Department of Medical Melanoma and Sarcoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China, Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Medical Melanoma and Sarcoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Phase 1b/2 study of surufatinib in combination with docetaxel as second-line treatment of advanced driver-gene negative non-squamous non-small cell lung cancer (NSCLC).Org: Department of Respiratory Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China, Guangxi Medical University Cancer Hospital, Nanning, China,